Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of ellagic acid to preparation of medicine for preventing and/or treating nonalcoholic fatty liver disease and liver injury

A technology for non-alcoholic fatty liver disease, which is applied in the field of ellagic acid in the preparation of drugs for preventing and/or treating non-alcoholic fatty liver disease and liver damage, and achieves the effects of protecting liver cells and reducing oxidative stress damage

Inactive Publication Date: 2021-02-02
SICHUAN UNIV
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although many Nrf2 agonists (such as curcumin and resveratrol, etc.) of traditional Chinese medicine and natural medicine monomers are undergoing clinical trials, they still face many difficulties and challenges in the process of development.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of ellagic acid to preparation of medicine for preventing and/or treating nonalcoholic fatty liver disease and liver injury
  • Application of ellagic acid to preparation of medicine for preventing and/or treating nonalcoholic fatty liver disease and liver injury
  • Application of ellagic acid to preparation of medicine for preventing and/or treating nonalcoholic fatty liver disease and liver injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0069] Example 1. Preliminary research on the therapeutic effect and mechanism of EA and MoA on NAFLD mouse model

[0070] 1. Establishment and verification of NAFLD mouse model

[0071] 1.1 Experimental animal grouping, feeding and sample collection

[0072] 12 wild-type and Nrf2 knockout homozygous (Nrf2- / -) C57BL / 6 mice (bred by our laboratory) were selected, and the mice were randomly divided into 2 groups (same genotype), 6 in each group, male and female Half and half. After 1 week of adaptive feeding with 12h light and 12h darkness alternately, they were fed with high-fat feed for 2 months. See Table 2-1 for grouping and feeding scheme.

[0073] Table 2-1 Grouping and feeding scheme of mice (n=6).

[0074]

[0075] After feeding for 2 months, mice were anesthetized by intraperitoneal injection of 10% chloral hydrate (0.5g / kg). The liver tissue was soaked in 4% paraformaldehyde fixative, and the remaining liver tissue was stored at -70°C until use. Whole blood was...

Embodiment 2

[0237] Example 2. In vitro cell model verification of the therapeutic effect of EA and MoA on NAFLD through the Nrf2 pathway In this example, except for the following drugs, the sources of other drugs are the same as above:

[0238] Reactive oxygen species (ROS) test box (E004, built in Nanjing); fatty acid-free-BSA (B2064, SIGMA, USA); oleic acid (O1383, SIGMA, USA); palmitic acid (P0500, SIGMA, USA).

[0239] 1. Establishment and verification of NAFLD cell model

[0240] 1.1 Solution preparation

[0241] 1) 1640 complete medium: same as Example 1.

[0242] 2) DMEM complete medium: same as Example 1.

[0243] 3) 0.25% trypsin: same as Example 1.

[0244] 4) PBS solution: Take a bag of PBS powder, add 1L UP water according to the instructions, mix well, and set aside.

[0245] 5) 20% fatty acid-free-BSA solution: Weigh 0.6g of fatty acid-free-BSA, put it in a 50mL centrifuge tube, add 3mL of PBS solution preheated to 55°C, and centrifuge directly at room temperature (about...

Embodiment 3

[0463] Example 3. Study on the preventive effect and mechanism of EA and MoA on APAP liver injury in NAFLD mouse model

[0464] In this experimental example, except for the following drugs, the sources of other drugs are the same as above: acetaminophen suspension drops (Tylenol, Shanghai Johnson Pharmaceutical Co., Ltd.).

[0465] 1.1 Determination of APAP administration time

[0466] 1.1.1 Experimental animal grouping, drug administration and sample collection

[0467] Eighteen wild-type C57BL / 6 mice bred in our laboratory were selected and randomly divided into three groups, with six mice in each group, half male and half male. After 1 week of adaptive feeding with 12h light and 12h darkness alternately, the treatment group was given the maximum safe dose of APAP (150mg / kg) by intragastric administration at 9:00 in the morning (APAP-AM) and 5:00 in the afternoon (APAP-PM). Administration for 3 days, once a day. See Table 4-1 for grouping and dosing regimen.

[0468] Tab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of ellagic acid to preparation a medicine for preventing and / or treating a nonalcoholic fatty liver disease and liver injury. The invention proves that the ellagic acid is an Nrf2 agonist, and by up-regulating expression of Nrf2 and downstream antioxidant factors and transporters thereof, the ellagic acid increases the level of glutathione (GSH) in the liver, andmeanwhile, reduces the level of reactive oxygen species (ROS) in hepatocytes, oxidative stress reaction and inflammatory reaction are reduced, the functions of hepatocytes are maintained, and therefore the effect of treating the nonalcoholic fatty liver disease (NAFLD) is achieved. In addition, the ellagic acid can increase the level of the GSH in the liver by up-regulating the expression of Nrf2and the downstream antioxidant factors and transporters thereof, so that the hepatotoxicity of a normal dose of N-acetyl-p-aminophenol (APAP) increased by the NAFLD is prevented. The ellagic acid hasgood application prospects in the preparation of NAFLD treatment drugs and APAP hepatotoxicity prevention drugs.

Description

technical field [0001] The invention belongs to the field of medicines, and in particular relates to the use of ellagic acid in the preparation of medicines for preventing and / or treating non-alcoholic fatty liver disease and liver damage. Background technique [0002] Nonalcoholic fatty liver disease (NAFLD) is a metabolic stress-induced liver injury associated with genetic predisposition and insulin resistance. The pathological feature of this clinical disease was hepatic steatosis and the patient had no history of excessive alcohol consumption. The disease spectrum of NAFLD includes: non-alcoholic simple fatty liver, non-alcoholic steatohepatitis (Nonalcoholic steatohepatitis, NASH) and its related liver cirrhosis and hepatocellular carcinoma (Hepatocellularcarcinoma, HCC). NAFLD can not only lead to disability and death related to liver disease, but also closely related to the high incidence of metabolic syndrome, type II diabetes and atherosclerotic cardiovascular dise...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/366A61P1/16
CPCA61K31/366A61P1/16
Inventor 余璐王凌蒋学华
Owner SICHUAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com